Hengsai Biologicals Completes $100 Million Series A Financing

Recently, following the completion of tens of millions of financing last year, Hengsai Biological has successfully completed the 100 million yuan A round of financing again this year. This financing is provided byFuhui Venture CapitalLeading the investment.Chintz Capital,Knight Rider Kang YingFollow-through.M劢 Capitalacted as the exclusive financial advisor.

Founded in 2018, Hengsai Bio is a scientific and technological innovative enterprise and national high-tech enterprise dedicated to the research, development and industrialization of dendritic cell vaccines (DC vaccines). The company has successfully constructed the Eco-DCVax platform, aiming to break down the technical barriers to industrialization and develop global First-in-Class high-quality DC vaccine products with independent property rights that are safe, efficient and convenient to administer. The developed product, therapeutic dendritic cell vaccine, provides a new approach and strategy for the treatment of relapsed and refractory tumors, chronic viral infections, autoimmune diseases and other diseases that are in urgent need of effective clinical treatments.

Hengsai Bio's R&D center and pilot plant in Shanghai Lingang Blue Bay officially came into operation in 2021, and a large-scale R&D/production base is under construction. The company has now established stable cooperative relationships with a number of domestic and foreign research institutions and tertiary hospitals, and is in the process of dual-reporting between China and the U.S. to carry out clinical research and technical cooperation in order to comprehensively verify the clinical safety and effectiveness of the DC vaccine.

At present, there is no approved DC vaccine product in China. Hengsai Biological has now built a complete DC vaccine comprehensive R&D platform and technology system, including DC cell separation and induction technology at the international leading level, tumor antigen selection and loading platform, clinical trial level DC cell production center, quality control and management system, and so on. On the basis of cutting-edge overseas DC vaccine R&D experience, the company has further improved and established a standardized and regulated DC vaccine production method, which is convenient for industrialization. The overall technical level is in the international leading position, and we own a number of invention patents, which fill the gaps in this field in China.

Dr. Liu Huining, Founder and CEO of Hengsai Biologicals Inc.Hengsai Bio has a mature DC vaccine preparation process and a scientific and compliant quality control system. We are very grateful to our investors, Fortune Venture Capital, Qinzhi Capital and Kemper Capital, for their recognition and trust in our company, as well as the support of MaiPai Capital. This round of financing will help us advance our product pipeline and clinical filings. The Hengsai team will continue to develop safer, long-lasting, and more affordable DC vaccines by focusing on clinical needs and driven by technological innovation. 

Fortune Ventures Investment TeamIt means: With the deep strategic cooperation with Shanghai Institute of Pharmaceutical Sciences of Chinese Academy of Sciences and Zhongshan Municipal Government, Fortune Venture Capital has been committed to promoting the development of more high-quality innovative drug companies in Cuiheng New District of Zhongshan City for a long period of time. Hengsai Bio, as a leading DC cell therapy company in China, is a representative of the high-quality enterprises we have cooperated with for a long time, and we will continue to help Hengsai Bio to develop rapidly and grow into a leading DC cell therapy company in the world.

Qinzhi Capital Investment Teamsaid: Hengsai Biological's new generation DC vaccine technology has many advantages, which makes it have a wide range of application prospects. The company's core founding team has many years of experience in cell therapy, has established a relatively mature DC vaccine preparation process, and has a scientifically compliant quality control system, all of which will contribute to the company's long-term sound development. We expect Hengsai Bio's DC vaccine to bring positive impact and substantial help to patients as soon as possible.

Bo Chen, Managing Partner of Knight Rider Kang YingHengsai Bio-developed the international leading DC vaccine culture technology, which makes the antigen versatility and effectiveness get the best expression, and creates a new way of tumor vaccine with remarkable efficacy and easy to be industrialized, and we are looking forward to seeing that Hengsai can continue to conquer many kinds of viruses caused by the tumor disease, and benefit the patients with this kind of "terminal disease".

Huanxing Ding, Partner at M劢 CapitalMr. Sheng said: DC vaccine has the advantages of low cost, good efficacy, low side effects and convenient clinical use, etc. Hengsai Bio has made great progress in R&D rapidly following the last round of financing, and we believe that Hengsai Bio will lead the development of DC vaccine industry after this round of financing.

 Fortune Ventures is a VC investment organization focusing on the transformation of scientific and technological achievements and early-stage investment in science and technology enterprises, and has invested in a number of high-quality companies in the medical and healthcare field, including Nuohui Health (06606.HK), Eagle Pupil Technology (02251.HK), Cascade, Ziben Pharmaceuticals, Huazi Biologicals, Bajie Hongye, Uri Pharmaceuticals, Luoqi Biologicals, Ruishun Biologicals, and so on.

Shenzhen Qianhai Qinzhi International Capital Management Co., Ltd. brings together senior industry professionals from SZV, Roche, GSK, BMS, Abbvie, AstraZeneca, UW Life, etc., with offices in Shenzhen, Shanghai, Hangzhou, Changzhou, Dongguan, Zhongshan, etc., and has initiated and set up nearly forty RMB and US dollar funds. In January 2023, the company was honored as one of the "Top 30 Growth-oriented VC Investment Institutions in China in 2022" in the annual list of China's venture capital industry.

Cavalcade is an industrial investment firm specializing in investing in cutting-edge biopharmaceutical companies. It consists of experienced healthcare investors who have invested in a number of early-stage companies with extremely high growth potential.

MedBio Capital is a boutique investment bank specializing in the life sciences and healthcare sectors, dedicated to being a capital and strategic partner to top scientists and entrepreneurs. MedBio Capital's core team has been deeply involved in the healthcare industry for many years, covering key nodes of R&D, clinical and marketing, and has a strong background in investment, investment banking and consulting. The team members have completed a total of over 10 billion dollars in financing, and have served more than ten top medical listed companies.

- END -